Q-linea to participate in a multi-site public tender in Italy

Q-linea AB (publ) (OMX: QLINEA) announces participation in the 5-year Tender published by ASL Napoli 2 Nord for 4 rAST systems.

The tender has been issued following the recent publication of updated guidelines on "Diagnosis and Management of Infections from Multidrug Resistant Bacterias" aiming to reduce identification and phenotypic antibiogram times for the administration of effective antibiotic therapy. The updated guidelines have been agreed by several Italian scientific societies as one of the ways to improve therapy in critically ill patients.

Expectations are for the tender process to be completed by the end of Q1 and installations operative in Q2 2025.

"The publication of this Tender is another indication of the ever-growing importance of rAST in Italy as a key pillar in the treatment of critical patients and the proper use of antibiotics in Italy", said Franco Pellegrini, VP Sales EMEA at Q-linea.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Q-linea to participate in a multi-site public tender in Italy